GSK: Under Threat From 'Double Whammy' Of Vaccine Skepticism And Pharma Tariffs
Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are ...
GSK employees perform anonymous ‘180’ surveys on their bosses, and CEO Emma Walmsley isn’t exempt
When I’ve made mistakes on people, it’s usually for cultural reasons,” Walmsley told Norges Bank Investment Management CEO ...
American Association of Individual Investors1d
Which Is a Better Investment, Corcept Therapeutics Incorporated or GSK plc Stock?
Learn more about whether Corcept Therapeutics Incorporated or GSK plc is a better investment based on AAII's A+ Investor ...
Why GSK (GSK) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is GSK plc (GSK) the Best ADR Stock to Buy According to Hedge Funds?
We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take ...
GSK's Vaccine and HIV Portfolios Support Ongoing Innovation in Oncology and Immunology
GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...
Scripps News7d
FDA approves first new antibiotic treatment for UTIs in decades
A new antibiotic has been approved to treat urinary tract infections by the Food and Drug Administration for the first time ...
ViiV Healthcare's APRETUDE Now Covered Under Canada's NIHB Program For HIV Prevention
ViiV Healthcare, a global specialist HIV company majority-owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, Wednesday announced that APRETUDE ...
FDA approves new antibiotic to treat UTIs in females
The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...
Le Lézard7d
ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce that APRETUDE (cabotegravir ...
BioSpace7d
GSK Wins FDA Nod for First Oral UTI Antibiotic in Almost 30 Years
Blujepa, which treats UTIs in female patients aged 12 and up with common and uncomplicated infections, will hit the market in ...